In prostate cancer, FOXA1 mutations are generally categorized into three classes: Class-1 (missense mutations in the Wing2 region), Class-2 (C-terminal truncating mutations), and Class-3 (structural variants), which are predominantly associated with early-stage cancer, metastatic cancer, and advanced malignancies, respectively. This evidence concerns the gene FOXA1 and cancer.